Skip to main content

Dr. Gary C. Steven, M.D.

Allergy & Immunology (Allergy Physician)

8585 W Forest Home Ave, Suite 200
Greenfield, WI 53228

Who else practices at this address →

Milwaukee County includes primary care (32% of residents) and mental health (34% of residents) shortage areas. About shortage areas

Call (414) 529-8500

  • Medicare participating

At a glance

Medical school
Medical College of Wisconsin (1991)
Years since graduation
35
In the NPI registry since
2006
Medicare patients seen, 2024
189

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1991Medical school: Medical College of Wisconsin
  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Allergy Physician primary
    WI license 33574020
  • Specialist
    WI license 33574020

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Allergy & Immunology per capita by county →

Where they work

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
189
Services billed
5,830
Patients’ average age
71
Most frequent Medicare services, 2023
ServiceTimesPatients
Professional service for preparation and provision of 1 or more antigens76636
Professional service for multiple injections of allergen51843
Established patient office or other outpatient visit, 30-39 minutes8055
Established patient office or other outpatient visit, 20-29 minutes7471
Test to measure the level of nitric oxide gas2925
Test to measure expiratory airflow and volume2825
New patient office or other outpatient visit, 30-44 minutes2121
Administration of influenza virus vaccine1313
Influenza vaccine split virus, preservative free1111

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 16 companies reported 112 payments worth $14,396 in total to this clinician.

By type
Compensation for services other than consulting (speaking, faculty)$9,300
Food and Beverage$4,016
Travel and Lodging$946
Education$133

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Apr 23, 2025AstraZeneca Pharmaceuticals LP
Apr 23, 2025
Compensation for services other than consulting (speaking, faculty)
AIRSUPRA · Respiratory
Company’s descriptionSpeaker Fee
$3,700
Apr 7, 2025AstraZeneca Pharmaceuticals LP
Apr 7, 2025
Compensation for services other than consulting (speaking, faculty)
AIRSUPRA · Respiratory
Company’s descriptionSpeaker Fee
$3,700
Jul 24, 2025AstraZeneca Pharmaceuticals LP
Jul 24, 2025
Compensation for services other than consulting (speaking, faculty)
AIRSUPRA · Respiratory
Company’s descriptionSpeaker Fee
$1,400
Mar 27, 2025AstraZeneca Pharmaceuticals LP
Mar 27, 2025
Travel and Lodging
AIRSUPRA · Respiratory · travel to Rockford, IL · in-kind
Company’s descriptionSpeaker Expenses
$747
Mar 27, 2025AstraZeneca Pharmaceuticals LP
Mar 27, 2025
Compensation for services other than consulting (speaking, faculty)
AIRSUPRA · Respiratory
Company’s descriptionSpeaker Fee
$250
May 29, 2025AstraZeneca Pharmaceuticals LP
May 29, 2025
Compensation for services other than consulting (speaking, faculty)
AIRSUPRA · Respiratory
Company’s descriptionSpeaker Fee
$250
Sep 24, 2025Regeneron Healthcare Solutions, Inc.
Sep 24, 2025
Education
DUPIXENT · IMMUNOLOGY AND INFLAMMATION · in-kind
$99.26
May 23, 2025AstraZeneca Pharmaceuticals LP
May 23, 2025
Travel and Lodging
travel to Denver, CO
Company’s descriptionResearch Related Service
$71.74
Jul 9, 2025AstraZeneca Pharmaceuticals LP
Jul 9, 2025
Travel and Lodging
travel to Denver, CO
Company’s descriptionResearch Related Service
$51.00
May 23, 2025AstraZeneca Pharmaceuticals LP
May 23, 2025
Travel and Lodging
travel to Denver, CO
Company’s descriptionResearch Related Service
$37.40
All 13 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Sep 24, 2025Regeneron Healthcare Solutions, Inc.
Sep 24, 2025
Education
DUPIXENT · IMMUNOLOGY AND INFLAMMATION · in-kind
$99.26
Sep 3, 2025Amgen Inc.
Sep 3, 2025
Education
in-kind
$34.00
Jul 24, 2025AstraZeneca Pharmaceuticals LP
Jul 24, 2025
Compensation for services other than consulting (speaking, faculty)
AIRSUPRA · Respiratory
Company’s descriptionSpeaker Fee
$1,400
Jul 9, 2025AstraZeneca Pharmaceuticals LP
Jul 9, 2025
Travel and Lodging
travel to Denver, CO
Company’s descriptionResearch Related Service
$51.00
Jul 9, 2025AstraZeneca Pharmaceuticals LP
Jul 9, 2025
Travel and Lodging
travel to Denver, CO
Company’s descriptionResearch Related Service
$20.74
Jun 30, 2025AstraZeneca Pharmaceuticals LP
Jun 30, 2025
Travel and Lodging
AIRSUPRA · Respiratory · travel to Waukesha, WI · in-kind
Company’s descriptionSpeaker Expenses
$18.20
May 29, 2025AstraZeneca Pharmaceuticals LP
May 29, 2025
Compensation for services other than consulting (speaking, faculty)
AIRSUPRA · Respiratory
Company’s descriptionSpeaker Fee
$250
May 23, 2025AstraZeneca Pharmaceuticals LP
May 23, 2025
Travel and Lodging
travel to Denver, CO
Company’s descriptionResearch Related Service
$71.74
May 23, 2025AstraZeneca Pharmaceuticals LP
May 23, 2025
Travel and Lodging
travel to Denver, CO
Company’s descriptionResearch Related Service
$37.40
Apr 23, 2025AstraZeneca Pharmaceuticals LP
Apr 23, 2025
Compensation for services other than consulting (speaking, faculty)
AIRSUPRA · Respiratory
Company’s descriptionSpeaker Fee
$3,700
Apr 7, 2025AstraZeneca Pharmaceuticals LP
Apr 7, 2025
Compensation for services other than consulting (speaking, faculty)
AIRSUPRA · Respiratory
Company’s descriptionSpeaker Fee
$3,700
Mar 27, 2025AstraZeneca Pharmaceuticals LP
Mar 27, 2025
Travel and Lodging
AIRSUPRA · Respiratory · travel to Rockford, IL · in-kind
Company’s descriptionSpeaker Expenses
$747
Mar 27, 2025AstraZeneca Pharmaceuticals LP
Mar 27, 2025
Compensation for services other than consulting (speaking, faculty)
AIRSUPRA · Respiratory
Company’s descriptionSpeaker Fee
$250

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Wisconsin →

Industry-funded research

Named as a principal investigator on 21 industry-funded studies in 2025, from 8 companies. The companies reported $1,269,262 in research payments for these studies, mostly to the institutions running them.

  • A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared …
    AstraZeneca Pharmaceuticals LP
  • A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect and Safety of PT007 AS MDI to Placebo MDI and Open-Label…
    AstraZeneca Pharmaceuticals LP
  • A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
    Eli Lilly and Company · Active, not recruiting · NCT06339008
  • Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630
    AstraZeneca Pharmaceuticals LP
  • A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (…
    Novartis Pharmaceuticals Corporation
  • Ph III OLE of Astegolimab in COPD
    Genentech, Inc.
  • A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate …
    AstraZeneca Pharmaceuticals LP
  • A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma
    AstraZeneca Pharmaceuticals LP
  • A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
    Teva Pharmaceuticals USA, Inc.
  • A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in…
    Teva Pharmaceuticals USA, Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Sources

NPI registry (CMS NPPES, November 2026; record last updated July 9, 2020), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1972530699. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.